solid tumor - Robuta Search

https://straitsresearch.com/report/solid-tumor-testing-market/toc Solid Tumor Testing Market Size & Share Report, 2033 solid tumor market size testing share report https://www.humaneticscorp.com/ Improving the Standard of Care for Solid Tumor Cancers Improving the Standard of Care for Solid Tumor Cancers standard of care solid tumor improving cancers https://www.ohsu.edu/providers/jacqueline-vuky-md Jacqueline Vuky, M.D. | Solid Tumor Specialist | OHSU m d solid tumor jacqueline vuky specialist https://www.pharmaceutical-technology.com/data-insights/emfizatamab-systimmune-solid-tumor-likelihood-of-approval/ Emfizatamab by Systimmune for Solid Tumor: Likelihood of Approval Dec 29, 2024 - Emfizatamab is under clinical development by Systimmune and currently in Phase I for Solid Tumor. solid tumor likelihood approval https://www.chop.edu/centers-programs/solid-tumor-program/resources Solid Tumor Program Resources | Children's Hospital of Philadelphia children s hospital solid tumor program resources philadelphia https://www.mayo.edu/research/clinical-trials/cls-20576228 Pediatric Extracranial Solid Tumor Biorepository - Mayo Clinic Learn more about services at Mayo Clinic. solid tumor pediatric biorepository mayo clinic https://www.frontiersin.org/research-topics/69533/advancements-in-solid-tumor-immunotherapy-enhancing-efficacy-and-overcoming-resistance/authors Frontiers | Advancements in Solid Tumor Immunotherapy: Enhancing Efficacy and Overcoming Resistance In oncology, immunotherapy stands as a transformative approach for treating solid tumors, notably through pioneering treatments like immune checkpoint inhibi... solid tumor frontiers advancements https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/06/new-division-chief-of-solid-tumor-oncology-announced New Division Chief of Solid Tumor Oncology Announced | University Hospitals Jorge A. Garcia, MD, FACP Joins UH Seidman Cancer Center solid tumor new division chief oncology https://ymmunobio.com/ Ymmunobio AG | First-in-Class Solid Tumor Therapeutics Apr 28, 2026 - Ymmunobio AG develops first-in-class therapeutics for solid tumors, targeting NPTXR, a tumor-exclusive marker found in 17+ major cancer types. in class solid tumor ag first therapeutics https://www.ohsu.edu/providers/jeff-donovan-pa-c Jeff Donovan | Solid Tumor Specialist | OHSU Meet Jeff Donovan, an OHSU physician assistant who specializes in caring for patients with cancer, especially gastrointestinal cancers. solid tumor jeff donovan specialist ohsu https://www.cancer.gov/publications/dictionaries/cancer-terms/def/solid-tumor Definition of solid tumor - NCI Dictionary of Cancer Terms - NCI NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. definition of solid tumor nci dictionary cancer https://www.nationwidechildrens.org/research/clinical-research/cancer-clinical-research/sarcoma-and-solid-tumor-studies Sarcoma and Solid Tumor Clinical Studies | Nationwide Children's Hospital Learn more about clinical research relating to sarcomas and solid tumors. solid tumor clinical studies sarcoma nationwide children https://www.news-medical.net/news/20250613/Boosting-CAR-T-cell-survival-to-improve-solid-tumor-therapy.aspx Boosting CAR T cell survival to improve solid tumor therapy Jun 13, 2025 - Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their... car t cell solid tumor boosting survival improve https://www.pennmedicine.org/news/penn-developed-car-t-cells-suppress-gi-solid-tumor-cells-without-toxicity-to-healthy-tissue CAR T cells suppress GI solid tumor cells without damage | Penn Medicine Early research shows that targeting the molecule CDH17 with CAR T cells represents a new approach to treat solid cancers. car t cells solid tumor suppress gi https://www.wikidata.org/wiki/Q51904857 The fuzzy math of solid tumor stem cells: a perspective - Wikidata scientific article published in October 2007 tumor stem cells fuzzy math solid https://www.chop.edu/centers-programs/solid-tumor-program/research-studies Solid Tumor Program Research Studies | Children's Hospital of Philadelphia children s hospital solid tumor research studies program philadelphia https://www.researchandmarkets.com/reports/6056874/solid-tumor-testing-market-report-trends Solid Tumor Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 Solid Tumor Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 solid tumor market report https://www.fiercebiotech.com/biotech/chinas-hanxbio-plans-hong-kong-ipo-fund-phase-2-solid-tumor-trial HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial Nov 25, 2024 - HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. hong kong https://www.wikidata.org/wiki/Q40861131 Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. - Wikidata scientific article published on August 2000 hypoxia inducible factor https://www.fda.gov/about-fda/oncology-center-excellence/modeling-pediatric-solid-tumors-and-tumor-microenvironment Modeling Pediatric Solid Tumors and the Tumor Microenvironment | FDA Modeling Pediatric Solid Tumors and the Tumor Microenvironment solid tumors modeling pediatric microenvironment fda https://www.virtualcancercure.com/ CancerMate: a revolutionary tool for personalized and precision monitoring of solid tumor care -... Feb 26, 2026 - CancerMate is a software application designed for the optimization of clinical care of solid tumor. The focus is to quantify lesion volumes (in the sense of... https://www.mskcc.org/cancer-care/clinical-trials/25-316 A Study of SLV-154 in People With Solid Tumor Cancer | Memorial Sloan Kettering Cancer Center Full Title A Phase 1 Dose-Escalation Study of SLV-154 in Subjects with Metastatic Solid Tumors Purpose To learn more about the purpose of this study and to... https://www.benzinga.com/general/biotech/21/06/21446975/harpoons-tritac-programs-show-reduction-in-tumor-size-stable-disease-across-solid-tumors Harpoon's TriTAC Programs Show Reduction in Tumor Size, Stable Disease Across Solid Tumors -... https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58454&ver=42&= Article - Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers... Use this page to view details for the Local Coverage Article for Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers. billing and coding minimal residual disease https://www.frontiersin.org/research-topics/69626/noncoding-rnas-in-the-tumor-immune-microenvironment-drivers-of-solid-tumor-evolution-and-therapeutic-potential/authors Frontiers | Noncoding RNAs in the Tumor Immune Microenvironment: Drivers of Solid Tumor Evolution... The tumor microenvironment (TME) represents a complex ecosystem that involves a dynamic interplay between cancer cells, immune cells, stromal components, and... in the https://www.einpresswire.com/article/317597249/genmab-announces-studies-of-daratumumab-in-combination-with-atezolizumab-in-a-solid-tumor-and-multiple-myeloma Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and... Mar 21, 2016 - Company Announcement Phase Ib studies of daratumumab in combination with Roche's immune checkpoint inhibitor atezolizumab in a solid tumor and multiple myeloma https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1090429/full Frontiers | Manipulating T-cell metabolism to enhance immunotherapy in solid tumor Cellular metabolism is not only essential for tumor cells to sustain their rapid growth and proliferation, but also crucial to maintain T cell fitness and ro... t cell frontiers manipulating metabolism https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58454&ver=30&= Article - Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers... Use this page to view details for the Local Coverage Article for Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers. billing and coding minimal residual disease https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1474343/full Frontiers | Abscopal effect of focused ultrasound combined immunotherapy in animal solid tumor... IntroductionThe abscopal effect, a systemic anti-tumor response triggered by localized treatment, has gained attention but remains poorly understood. This st... abscopal effect focused ultrasound https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58454&ver=33&= Article - Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers... Use this page to view details for the Local Coverage Article for Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers. billing and coding minimal residual disease https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58454&ver=45&= Article - Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers... Use this page to view details for the Local Coverage Article for Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers. billing and coding minimal residual disease https://www.prnewswire.com/news-releases/immunofoco-earns-spot-on-forbes-asia-100-to-watch-2025-list-for-leading-new-wave-in-solid-tumor-cell-therapy-302547520.html Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor... /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the... https://www.spandidos-publications.com/10.3892/or.2023.8543 Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a... Oncology Reports is an international journal devoted to fundamental and applied research in Oncology. https://www.mskcc.org/cancer-care/clinical-trials/25-361 A Study of LY4257496 in People With Solid Tumor Cancer | Memorial Sloan Kettering Cancer Center Full Title OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand...